Severe growth failure

The PBS subsidises mecasermin for paediatric patients with severe growth failure with primary insulin-like growth factor-1 deficiency (IGFD).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with mecasermin under the National Health Act 1953, section 100 for patients aged 2 to 17 years old (inclusive) with severe growth failure with primary insulin-like growth factor-1 deficiency (IGFD).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing mecasermin.

Section 100 arrangements

Mecasermin

This item is PBS-subsidised under Section 100 and can be dispensed by a:

  • community pharmacy
  • participating PBS reform public hospital pharmacy
  • private hospital pharmacy
  • dispensing doctor.

Treatment specifics

To be eligible for PBS-subsidised treatment with mecasermin, patients must be treated by and the medication must be prescribed by a paediatric endocrinologist or a paediatrician in consultation with a paediatric endocrinologist.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised mecasermin to treat severe growth failure with IGFD can be made either in:

All written applications must include the completed:

Applying for initial grandfather treatment

Applications for initial grandfather authority approval to prescribe PBS-subsidised mecasermin to treat severe growth failure with IGFD can be made either in:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised mecasermin to treat severe growth failure with IGFD can be made either in:

All written applications must include the completed:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 October 2022